Dyadic Announces Second Quarter 2023 Financial Results and Highlights Recent Company Progress

by B2i | Aug 9, 2023 | Press Releases

Positive Interim Phase 1 clinical trial safety results for C1 platform for manufacturing human vaccines Two MoU’s with Fondazione Biotecnopolo di Siena in Italy and Essential Drugs Company Limited (EDCL) in Bangladesh Progress in developing animal-free...

Dyadic Announces Continued Progress Towards Commercialization of Animal-Free Recombinant Serum Albumin

by B2i | Aug 7, 2023 | Press Releases

JUPITER, Fla., Aug. 07, 2023 — Dyadic International, Inc. (“Dyadic”, “we”, “us”, “our”, or the “Company”) (NASDAQ: DYAI), a global biotechnology company focused on building innovative microbial...

Dyadic to Report Second Quarter 2023 Financial Results on Wednesday, August 9, 2023

by B2i | Jul 26, 2023 | Press Releases

JUPITER, Fla., July 26, 2023 — Dyadic International, Inc. (“Dyadic”, “we”, “us”, “our”, or the “Company”) (NASDAQ: DYAI), a global biotechnology company focused on building innovative microbial...

Dyadic Provides Phase 1 Clinical Trial Update for its Recombinant Protein RBD Vaccine Candidate

by B2i | Jul 24, 2023 | Press Releases

Dosing of patients completed at the end of FebruaryData Safety Monitoring Board conducted analysis of Day 29 data No major vaccine-related safety concerns for either of the two dose levelsNo Serious Adverse Events (SAE’s) or Adverse Events of Special Interest...

Dyadic Announced an MoU with Bangladesh’s State-Owned Pharmaceutical Company to Facilitate Biopharmaceutical Research and Biomanufacturing Capacity

by B2i | Jun 21, 2023 | Press Releases

JUPITER, Fla. and DHAKA, Bangladesh, June 21, 2023 — Dyadic International, Inc. (“Dyadic”, “we”, “us”, “our”, or the “Company”) (NASDAQ: DYAI), a global biotechnology company focused on building...